Overview

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Status:
Recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, uncontrolled study design to evaluate the longer-term safety profile as well as durability of response of administration of a single dose level of CC-93538. The study will enroll participants who participated in the CC-93538-EE-001 study.
Phase:
Phase 3
Details
Lead Sponsor:
Celgene